Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2

[1]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[2]  Richard Welford.  E. H. A. , 1900 .

[3]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[4]  장윤희,et al.  Y. , 2003, Industrial and Labor Relations Terms.

[5]  A. ADoefaa,et al.  ? ? ? ? f ? ? ? ? ? , 2003 .

[6]  R. Sun,et al.  mRNA Display Design of Fibronectin-based Intrabodies That Detect and Inhibit Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein* , 2009, The Journal of Biological Chemistry.

[7]  J. Torres,et al.  Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel , 2009, PLoS pathogens.

[8]  K. Yuen,et al.  Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication. , 2009, Hong Kong medical journal = Xianggang yi xue za zhi.

[9]  James P. Evans.  The Origin , 2009, Genetics in Medicine.

[10]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[11]  D. Meyerholz,et al.  Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae , 2009, Journal of Virology.

[12]  D. Barnard,et al.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. , 2011, Future virology.

[13]  P. Mortensen.  EPIDEMIOLOGY , 2012, Schizophrenia Research.

[14]  S. Sarafianos,et al.  Severe Acute Respiratory Syndrome Coronavirus Replication Inhibitor That Interferes with the Nucleic Acid Unwinding of the Viral Helicase , 2012, Antimicrobial Agents and Chemotherapy.

[15]  D. Montefiori,et al.  Activity of and Effect of Subcutaneous Treatment with the Broad-Spectrum Antiviral Lectin Griffithsin in Two Laboratory Rodent Models , 2013, Antimicrobial Agents and Chemotherapy.

[16]  J. Epstein,et al.  Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor , 2013, Nature.

[17]  L. Segal.  John , 2013, The Messianic Secret.

[18]  G. Khan.  A novel coronavirus capable of lethal human infections: an emerging picture , 2013, Virology Journal.

[19]  P. Roy,et al.  virus-like particles , 2022, CABI Compendium.

[20]  Shibo Jiang,et al.  A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein , 2014, Journal of Virology.

[21]  S. Sarafianos,et al.  Evaluation of SSYA10-001 as a Replication Inhibitor of Severe Acute Respiratory Syndrome, Mouse Hepatitis, and Middle East Respiratory Syndrome Coronaviruses , 2014, Antimicrobial Agents and Chemotherapy.

[22]  R. Baric,et al.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution , 2014, Proceedings of the National Academy of Sciences.

[23]  J. Aronson.  Safety , 2009, BMJ : British Medical Journal.

[24]  C. Bor,et al.  Ventilator-associated pneumonia in critically ill patients with intensive antibiotic usage , 2015, Pakistan journal of medical sciences.

[25]  A. Mesecar,et al.  The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds , 2014, Antiviral Research.

[26]  Gavin W K Wong,et al.  First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. , 2015, The Cochrane database of systematic reviews.

[27]  E. Graham,et al.  The utility of feline coronavirus antibody tests , 2014 .

[28]  Z. Memish,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction , 2015, Pathogens and global health.

[29]  A. Nagdev,et al.  Point-of-Care Multi-Organ Ultrasound Improves Diagnostic Accuracy in Adults Presenting to the Emergency Department with Acute Dyspnea , 2016, The western journal of emergency medicine.

[30]  S. Bavari,et al.  BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease , 2016, Journal of Infection and Public Health.

[31]  H. Koley,et al.  Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators , 2016, Scientific Reports.

[32]  A. Shamshiri,et al.  Incidence of Ventilator-Associated Pneumonia in Critically Ill Children Undergoing Mechanical Ventilation in Pediatric Intensive Care Unit , 2017, Children.

[33]  W. Gibson,et al.  Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis , 2019, Journal of Thrombosis and Thrombolysis.

[34]  B. Fielding,et al.  Coronavirus envelope protein: current knowledge , 2019, Virology Journal.

[35]  Y. Ilyin,et al.  Virus-Like Particles as an Instrument of Vaccine Production , 2019, Molecular Biology.

[36]  G. Neumann,et al.  2748. Single Intranasal (IN) Dose of M2SR (M2-Deficient Single Replication) Live Influenza Vaccine Protects Adults Against Subsequent Challenge with a Substantially Drifted H3N2 Strain , 2019, Open Forum Infectious Diseases.

[37]  Wenling Wang,et al.  High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses , 2019, Journal of Virology.

[38]  A. Pruijssers,et al.  Nucleoside analogues for the treatment of coronavirus infections , 2019, Current Opinion in Virology.

[39]  S. Novakowski,et al.  Delivery of mRNA to platelets using lipid nanoparticles , 2019, Scientific Reports.

[40]  J. Zhao,et al.  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.

[41]  Madeeha Kamal,et al.  Therapeutic management of patients with COVID-19: a systematic review , 2020, Infection Prevention in Practice.

[42]  N. Callewaert,et al.  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[43]  R. Welsh,et al.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.

[44]  L. Camporota,et al.  COVID-19 pneumonia: different respiratory treatments for different phenotypes? , 2020, Intensive Care Medicine.

[45]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[46]  Y. Hu,et al.  Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.

[47]  David W Smith,et al.  COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t , 2020, Microbiology Australia.

[48]  Deniz Korkmaz,et al.  COVIDiagnosis-Net: Deep Bayes-SqueezeNet based diagnosis of the coronavirus disease 2019 (COVID-19) from X-ray images , 2020, Medical Hypotheses.

[49]  Jingfen Jin,et al.  Application of refined management in prevention and control of the coronavirus disease 2019 epidemic in non-isolated areas of a general hospital , 2020, International Journal of Nursing Sciences.

[50]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[51]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[52]  A. Cope,et al.  Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence , 2020, Ecancermedicalscience.

[53]  COVID-19 Vaccine Candidates , 2020 .

[54]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[55]  H. Kirking,et al.  First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA , 2020, The Lancet.

[56]  Sandro G. Viveiros Rosa,et al.  Clinical trials on drug repositioning for COVID-19 treatment , 2020, Revista panamericana de salud publica = Pan American journal of public health.

[57]  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[58]  R. Owens,et al.  Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike , 2020, Cell Host & Microbe.

[59]  P. Middleton,et al.  Ongoing Clinical Trials for the Management of the COVID-19 Pandemic , 2020, Trends in Pharmacological Sciences.

[60]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[61]  Santosh Kumar,et al.  Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19 , 2020, Viruses.

[62]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[63]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[64]  B. Song,et al.  Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review , 2020, European Radiology.

[65]  J. M. Abduljalil,et al.  Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view , 2020, New microbes and new infections.

[66]  Yongsheng Wu,et al.  Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study , 2020, The Lancet Infectious Diseases.

[67]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[68]  D. Cucinotta,et al.  WHO Declares COVID-19 a Pandemic , 2020, Acta bio-medica : Atenei Parmensis.

[69]  Shibo Jiang,et al.  Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. , 2020, Antiviral research.

[70]  Xiaokun Li,et al.  New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention , 2020, Frontiers in Cell and Developmental Biology.

[71]  Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody , 2020, Science.

[72]  M. Hall,et al.  Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 , 2020, ACS central science.

[73]  S. Rahimi,et al.  Epidemiological and Clinical Aspects of COVID-19; a Narrative Review , 2020, Archives of academic emergency medicine.

[74]  G. Pawelec,et al.  Can an effective SARS-CoV-2 vaccine be developed for the older population? , 2020, Immunity & Ageing.

[75]  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[76]  Cheorl-Ho Kim.  SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus–Host Interaction , 2020, International journal of molecular sciences.

[77]  H. Rothan,et al.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.

[78]  L. Poon,et al.  Emergence of a novel human coronavirus threatening human health , 2020, Nature Medicine.

[79]  S. Blomqvist,et al.  Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[80]  W. Cao,et al.  Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia , 2020, Emerging microbes & infections.

[81]  S. Mahalingam,et al.  Development of vaccines for SARS-CoV-2 , 2020, F1000Research.

[82]  Hangyuan Guo,et al.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.

[83]  R. Owens,et al.  Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike , 2020, SSRN Electronic Journal.

[84]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[85]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[86]  J. Eisen,et al.  2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission , 2020, mSystems.

[87]  T. Kishimoto,et al.  Translating IL-6 biology into effective treatments , 2020, Nature Reviews Rheumatology.

[88]  N. Rezaei,et al.  Immune-epidemiological parameters of the novel coronavirus – a perspective , 2020, Expert review of clinical immunology.

[89]  Koichi Yuki,et al.  COVID-19 pathophysiology: A review , 2020, Clinical Immunology.

[90]  Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain , 2020, Nature communications.

[91]  Pramath Kakodkar,et al.  A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19) , 2020, Cureus.

[92]  Taiwen Li,et al.  High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa , 2020, International Journal of Oral Science.

[93]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[94]  P. Hotez,et al.  COVID-19 vaccine design: the Janus face of immune enhancement , 2020, Nature Reviews Immunology.

[95]  Qi Zhao,et al.  Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 , 2020, International journal of biological sciences.

[96]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[97]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[98]  K. Batra,et al.  Chest Imaging in Patients Hospitalized With COVID-19 Infection - A Case Series , 2020, Current Problems in Diagnostic Radiology.

[99]  Kam Y. J. Zhang,et al.  Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 , 2020, Microbial Pathogenesis.

[100]  S. Ghasemi,et al.  Genotype and phenotype of COVID-19: Their roles in pathogenesis , 2020, Journal of Microbiology, Immunology and Infection.

[101]  C. Hedrich,et al.  COVID-19: Immunology and treatment options , 2020, Clinical Immunology.

[102]  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.

[103]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[104]  H. Harapan,et al.  Recent advances in vaccine and immunotherapy for COVID-19 , 2020, Human vaccines & immunotherapeutics.

[105]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[106]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[107]  P. Lomoro,et al.  COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review , 2020, European Journal of Radiology Open.

[108]  M. E. El Zowalaty,et al.  From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans – Call for a One Health approach , 2020, One Health.

[109]  Xiuhua Hu,et al.  Progress and prospect on imaging diagnosis of COVID-19 , 2020, Chinese Journal of Academic Radiology.

[110]  G. Kroemer,et al.  Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses , 2020, Cell stress.

[111]  Jun Zheng.  SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat , 2020, International journal of biological sciences.

[112]  Shengqing Wan,et al.  Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations , 2020, Cell Discovery.

[113]  P. Young.  Disease X ver1.0: COVID-19 , 2020, Microbiology Australia.

[114]  Charmaine Butt,et al.  Deep learning system to screen coronavirus disease 2019 pneumonia , 2020, Applied Intelligence.

[115]  L. Xia,et al.  Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China , 2020, European Journal of Radiology.

[116]  P. Hsueh,et al.  Treatment options for COVID-19: The reality and challenges , 2020, Journal of Microbiology, Immunology and Infection.

[117]  M. Fain,et al.  SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes , 2020, GeroScience.

[118]  W. Ko,et al.  Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths , 2020, Journal of Microbiology, Immunology and Infection.

[119]  Zhènglì Shí,et al.  An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies , 2020, Emerging microbes & infections.

[120]  P. Asfar,et al.  Vasopressin and its analogues in shock states: a review , 2020, Annals of Intensive Care.

[121]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[122]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[123]  J. Rello,et al.  Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers , 2020, European Respiratory Journal.

[124]  Emily N. Ussery,et al.  Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[125]  R. Tiwari,et al.  COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics , 2020, Human vaccines & immunotherapeutics.

[126]  E. Choi,et al.  Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2 , 2020, Frontiers in Cell and Developmental Biology.

[127]  Han Zhang,et al.  Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis , 2020, Journal of the American College of Radiology.

[128]  M. Ciccozzi,et al.  Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant , 2020, Journal of Translational Medicine.

[129]  Lee-Jen Wei,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[130]  N. Curtis,et al.  Coronavirus Infections in Children Including COVID-19 , 2020, The Pediatric infectious disease journal.

[131]  J. M. Abduljali,et al.  Epidemiology, genome and clinical features of the pandemic SARS-CoV-2: a recent view , 2020, New Microbes and New Infections.

[132]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[133]  R. Taheri,et al.  Combination of Biodata Mining and Computational Modelling in Identification and Characterization of ORF1ab Polyprotein of SARS-CoV-2 Isolated from Oronasopharynx of an Iranian Patient , 2020, Biological Procedures Online.

[134]  G. Pedrazzini,et al.  Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms , 2020, Journal of Cardiac Failure.

[135]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[136]  C. Patel,et al.  In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing , 2020, Journal of Infection and Public Health.

[137]  J. Xia,et al.  Clinical Time Features and Chest Imaging of 85 Patients With COVID-19 in Zhuhai, China , 2020, Frontiers in Medicine.

[138]  E. Abu-Gharbieh,et al.  The Rationale for Potential Pharmacotherapy of COVID-19 , 2020, Pharmaceuticals.

[139]  Safety and Immunity of Covid-19 aAPC Vaccine , 2020, Case Medical Research.

[140]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[141]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[142]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[143]  Bin Liu,et al.  Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy , 2020, Antibody therapeutics.

[144]  F. Mancini,et al.  OMV Vaccines and the Role of TLR Agonists in Immune Response , 2020, International journal of molecular sciences.

[145]  J. Wang,et al.  Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of China’s Prevention and Control Strategy for the COVID-19 Epidemic , 2020, International journal of environmental research and public health.

[146]  J. Kim,et al.  Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.

[147]  T. Torres,et al.  Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic , 2020, American Journal of Clinical Dermatology.

[148]  Hai Yu,et al.  Recent Progress on the Versatility of Virus-Like Particles , 2020, Vaccines.

[149]  C. Rapezzi,et al.  COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? , 2020, Basic Research in Cardiology.

[150]  R. Xu,et al.  Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System , 2020, Frontiers in Bioengineering and Biotechnology.

[151]  M. Shi,et al.  Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients , 2020, Emerging microbes & infections.

[152]  T. Fan,et al.  CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China , 2020, Journal of Infection.

[153]  Ashish Ranjan Sharma,et al.  Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 , 2020, Frontiers in Pharmacology.

[154]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[155]  G. Ampanozi,et al.  Implications for forensic death investigations from first Swiss post-mortem CT in a case of non-hospital treatment with COVID-19 , 2020, Forensic Imaging.

[156]  O. Tsang,et al.  Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.

[157]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[158]  E. Ooi,et al.  Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development , 2020, EBioMedicine.

[159]  S. Khader,et al.  The protective and pathogenic roles of CXCL17 in human health and disease: Potential in respiratory medicine , 2020, Cytokine & Growth Factor Reviews.

[160]  Yhu-Chering Huang,et al.  Are children less susceptible to COVID-19? , 2020, Journal of Microbiology, Immunology and Infection.

[161]  Lisa E. Gralinski,et al.  Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody. , 2020, bioRxiv : the preprint server for biology.

[162]  J. Rico-Mesa,et al.  Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB , 2020, Current Cardiology Reports.

[163]  V. Prajapati,et al.  High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19 , 2020, European Journal of Pharmaceutical Sciences.

[164]  Danna Zhou,et al.  d. , 1840, Microbial pathogenesis.

[165]  P. Alam.  ‘K’ , 2021, Composites Engineering.

[166]  P. Alam.  ‘T’ , 2021, Composites Engineering: An A–Z Guide.

[167]  P. Alam,et al.  H , 1887, High Explosives, Propellants, Pyrotechnics.

[168]  P. Alam.  ‘L’ , 2021, Composites Engineering: An A–Z Guide.

[169]  P. Alam.  ‘A’ , 2021, Composites Engineering: An A–Z Guide.

[170]  P. Alam.  ‘S’ , 2021, Composites Engineering: An A–Z Guide.